SARS-CoV-2-IN-36 

SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC₅₀ of 2.37 μM and a K_d of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells^[1].

SARS-CoV-2-IN-36 (compound 58) inhibit the replication of the Wuhan (UC-1074),South African (RG2674), and UK (NVDBB-2220) SARS-CoV-2 variants, with IC50 values of 5.0 μM, 39.9 μM, and 5.2 μM, respectively. SARS-CoV-2-IN-36 alters cell morphology only at concentrations above ≥100 μM and does not inhibit Vero cell growth up to a concentration >100 μM^[1].
SARS-CoV-2-IN-36 (compound 58) lacks antiviral activity against two herpesviruses (varicella-zoster virus and human cytomegalovirus) in human embryonic lung fibroblasts. SARS-CoV-2-IN-36 shows a very low cytotoxicity also against embryonic lung fibroblasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PK analysis of plasma concentrations, with ± SD, after intranasal (IN) and oral (PO) administration in male C57BL6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

343.38

C₁₇H₂₁N₅O₃

[H]C(C(N[C@H](C(N[C@@H](CC1=CNC=N1)C=O)=O)CC2=CC=CC=C2)=O)N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Simone Di Micco, et al. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. Eur J Med Chem. 2022 Dec 15;244:114857.  [Content Brief]